Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference

Rhea-AI Summary

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the 2024 Cantor Global Health Conference, scheduled for September 17-19, 2024, in New York City. The company's CEO, Yuval Cohen, Ph.D., will be presenting at the event.

Key details of the presentation include:

• Date: September 17, 2024
• Time: 8:00 AM Eastern Time
• Location: InterContinental New York Barclay Hotel
• Format: Fireside chat with Cantor analyst Prakhar Agrawal

Dr. Cohen will also be available for one-on-one investor meetings during the conference. A webcast link for the presentation has been provided for those unable to attend in person.

NORWOOD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at the 2024 Cantor Global Health Conference, to be held September 17-19, 2024 in New York, NY. Dr. Cohen will participate in a fireside chat with Cantor analyst Prakhar Agrawal and participate in one-on-one investor meetings.

2024 Cantor Global Healthcare Conference
	Location: InterContinental New York Barclay Hotel
	Date: September 17, 2024
	Time: 8:00 Eastern Time
	Webcast: Click here

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is an oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACT:

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com

Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

FAQ

When is Corbus Pharmaceuticals (CRBP) presenting at the 2024 Cantor Global Health Conference?

Corbus Pharmaceuticals (CRBP) is presenting at the 2024 Cantor Global Health Conference on September 17, 2024, at 8:00 AM Eastern Time.

Who will be representing Corbus Pharmaceuticals (CRBP) at the 2024 Cantor Global Health Conference?

Yuval Cohen, Ph.D., the Chief Executive Officer of Corbus Pharmaceuticals, will be representing the company at the 2024 Cantor Global Health Conference.

Where will the 2024 Cantor Global Health Conference be held?

The 2024 Cantor Global Health Conference will be held at the InterContinental New York Barclay Hotel in New York, NY.

What type of presentation will Corbus Pharmaceuticals (CRBP) give at the 2024 Cantor Global Health Conference?

Corbus Pharmaceuticals (CRBP) will participate in a fireside chat with Cantor analyst Prakhar Agrawal at the 2024 Cantor Global Health Conference.

Will there be a webcast available for Corbus Pharmaceuticals' (CRBP) presentation at the 2024 Cantor Global Health Conference?

Yes, a webcast link has been provided for those who wish to view Corbus Pharmaceuticals' (CRBP) presentation at the 2024 Cantor Global Health Conference remotely.